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building (Li et al., 2004; Stern and Taylor, 1991; Stern and Keer, 1999; 
Zhao and Li, 2009). HAL causes a prolonged disruption (up to 6 h), 
whereas CLZ and other atypical antipsychotics induce an early onset 
but transient disruption (less than 6 h). Novel antipsychotics such as 
amisulpride and aripiprazole also exhibit a certain degree of inhibi-
tion on active maternal responses in a dose-dependent fashion (Li 
et al., 2005a). Chronic treatment with HAL or olanzapine via mini-
pumps or repeated daily injections significantly inhibits rat active 
maternal responses as well (Li et al., 2005b). It seems that antipsycho-
ticinduced inhibition on pup retrieval, pup licking and nest build-
ing may be an inherent feature of all currently available antipsychot-
ics (Li et al., 2004, 2005a; Silva et al., 2001; Stern and Taylor, 1991; 
Stern and Keer, 1999; Zhao and Li, 2009). Our recent work further 
identifies that sedation and suppression of maternal motivation are 
two important behavioral mechanisms underlying the disruptive 
effects of antipsychotic treatment on maternal behavior (Zhao and 
Li, 2009).
The present study investigated the neurochemical basis of antipsy-
chotic-induced disruptive effects on rat maternal behavior. For typi-
cal antipsychotics, it is generally assumed that they disrupt maternal 
behavior by blocking dopamine D2 receptors because they are pri-
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Abstract
Many antipsychotic drugs disrupt active components of maternal behavior such as pup approach, pup retrieval and nest build-
ing at clinically relevant doses in postpartum female rats. However, the neurochemical mechanisms underlying such a disrup-
tive effect remain to be determined. This study  examined the neurochemical mechanisms that mediate the disruptive effects 
of haloperidol (a typical  antipsychotic) and clozapine (an atypical antipsychotic) on rat maternal behavior. Postpartum rats 
were  administered with haloperidol (0.2 mg/kg, sc) or clozapine (10.0 mg/kg, sc) together with either vehicle  (saline or water), 
quinpirole (a selective dopamine D2/D3 agonist, 0.5 or 1.0 mg/kg, sc), or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selec-
tive 5-HT2A/2C agonist, 1.0 or 2.5 mg/kg, sc), and their maternal behaviors were tested at different time points before and after 
drug administration. Haloperidol  and clozapine treatment disrupted pup approach, pup retrieval, pup licking and nest build-
ing.  Pretreatment of quinpirole, but not DOI, dose-dependently reversed the haloperidol-induced disruptions.  In contrast, pre-
treatment of DOI, but not quinpirole, dose-dependently reversed the clozapine-induced  disruptions. Quinpirole pretreatment 
even exacerbated the clozapine-induced disruption of pup retrieval  and nest building. These findings suggest a double disso-
ciation mechanism underlying the disruption of  haloperidol and clozapine on rat maternal behavior. Specifically, haloperidol 
disrupts maternal behavior  primarily by blocking dopamine D2 receptors, whereas clozapine exerts its disruptive effect pri-
marily by  blocking the 5-HT2A/2C receptors. Our findings also suggest that 5-HT receptors are involved in the mediation of rat 
maternal behavior.
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1. Introduction
Maternal behavior in rats is a complex behavior that shares many 
features with human mothering behavior (Fleming and Corter, 1988). 
It is naturally expressed for the first time with the birth of the first 
litter. Within hours of parturition, the mother rat reconstructs the 
nest, retrieves the displaced pups, gathers them together in the nest 
site and adopts a nursing posture over the pups to permit suckling 
(Dollinger et al., 1980; Rosenblatt and Lehrman, 1963). The mother 
rat (dam) continues to exhibit maternal behavior (pup licking, pup 
retrieval, nest building and nursing) over the subsequent 3-week 
period, although as the pups mature, the intensity and quality of her 
behavior changes (Galef, 1981; Rosenblatt and Lehrman, 1963).
In recent years, we have used the rat maternal behavior as an eco-
logically relevant model to investigate the behavioral mechanisms of 
action of antipsychotic drugs and attempted to capture the possible 
side effects of antipsychotic medications on human parental behav-
iors. We and others have shown that clinically comparable doses 
of haloperidol (HAL), clozapine (CLZ), risperidone and quetiapine 
(~50%–70%, dopamine D2 occupancy) disrupt active components of 
rat maternal behavior, such as pup retrieval, pup licking and nest 
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2.3. Basic experimental procedure
Starting 2 or 3 days prior to the first possible expected parturition 
date, the subjects were monitored every morning for signs of partu-
rition. Once the dam was found with pups in the morning (that day 
was designated as Day 1 postpartum), the mother was transferred 
into a clean cage with wood shavings for bedding. Two shredded 
paper towels were also provided for nesting material. The litter was 
culled to 8 pups (4 males and 4 females with the most visible milk 
bands). Maternal behavior tests were conducted on one day between 
Days 6 and 8 postpartum.
2.4. Maternal behavior test
The basic procedure was similar to what has been described in 
Zhao and Li (2009). Using a laptop computer with an event recording 
program (JWatcher, http://www.jwatcher.ucla.edu/), we recorded 
various components of maternal behavior in an 8-min testing session 
at different time points before and after drug administration. Each 
test started by removing the 8 pups from the dam and destroying the 
nest. Ten seconds later, the pups were returned to the corner of the 
cage diagonal to the nest site or dam sleeping corner. When the sub-
ject picked up a pup in her mouth and carried it back to the nest site, 
it was referred to as a successful pup retrieval. The total number of 
pups retrieved was recorded. Approach latency was defined as the 
time taken for mother rats to approach and sniff the pups from the 
reunion. First and last pup retrieval latency was defined as the time 
elapsed from the first pup approach to the retrieval of the first and 
eighth pup into the nest, respectively. A score of 480 s was assigned 
to nonresponders who did not approach or retrieve the testing pups 
at all.
The occurrence of other behaviors was also recorded, including 
pup nursing behavior (a rat positioning herself over the pups with 
legs splayed to accommodate the pups, including hover, high and 
low crouching over postures), pup licking (a female rat placing its 
tongue on the anogenital area and the rest of a pup’s body), nest 
building (a rat picking up nesting material in her mouth and trans-
porting it back to the nest site or pushing the material with her fore-
paws toward the nest site). At the conclusion of the test, any unre-
trieved pups were returned to the nest site.
2.4.1. Experiment 1. Effects of pretreatment with quinpirole or DOI on 
haloperidol-induced maternal behavior deficits in rats
Forty-four postpartum rats were randomly assigned to one of 
the following six groups: VEH+VEH (n=4, sterile water or saline), 
VEH+HAL (n = 8), QUI-0.5+HAL (n = 8), QUI-1.0+HAL (n = 8), DOI-
1.0+HAL (n = 8), and DOI-2.5+HAL (n = 8). On the drug test day (1 
day on either Postpartum Day 6, 7, or 8), all subjects were tested 5 
times at different time points before and after drug administrations, 
with the first maternal behavior test starting at 30 min prior to the 
HAL or vehicle injection (i.e., baseline) and the other tests occur-
ring at 30, 60, 120 and 240min after HAL or vehicle injection. QUI, 
DOI or vehicle was injected s.c. twice with the first injection at 10 
min before and the second at 50 min after the HAL or vehicle injec-
tion.We adopted such an injection strategy because our preliminary 
data showed that injection of QUI at 10 min prior to the administra-
tion of HAL could optimally reverse its disruption on pup retrieval. 
Also, agonists were injected twice separately on the basis of their rel-
atively short duration of action and rapid peak plasma concentra-
tions (Deutch and Duman, 1996; Whitaker and Lindstrom, 1987).
2.4.2. Experiment 2. Effects of pretreatment with quinpirole or DOI on clo-
zapine-induced maternal behavior deficits in rats
The basic procedure was identical to that of Experiment 1 with the 
exception that CLZ was tested in this experiment instead of halo-
peridol. Forty-four postpartum rats were randomly assigned to one 
of the following six groups and their maternal behaviors were tested: 
VEH+VEH (n = 4, sterile water or saline), VEH+CLZ (n = 8), QUI-0.5+
marily dopamine D2 antagonists (Dragunow et al., 1990; Seeman et 
al., 1976), and because apomorphine, a dopamine receptor agonist, 
can reverse the inhibitory effects of haloperidol (Giordano et al., 
1990). However, solid evidence demonstrating that typical antip-
sychotics do act through this specific D2 mechanism is still lacking. 
For atypical antipsychotics (e.g., clozapine, olanzapine), because 
they generally have multiple-receptor binding profiles (Meltzer, 
1989; Miyamoto et al., 2005), it is hard to pinpoint their exact neu-
rochemical mechanisms. Most atypical antipsychotics possess a 
much more potent antagonism on the 5-HT2 receptor in addition to 
relatively weak antagonism on D2 receptor (Meltzer et al., 2003). It 
is thus possible that the disruptive effects of atypical antipsychot-
ics on maternal behavior could be attributed to their action on D2 
receptor alone (Kapur and Seeman, 2001) or to its dual action on 
both 5-HT2 and D2 receptors (Meltzer et al., 1989a,b) or on other 
receptors.
In the present study, we administered quinpirole, a selective D2/
D3 dopaminergic receptor agonist or 2,5-dimethoxy-4-iodo-amphet-
amine (DOI), a selective 5-HT2A/2C serotonergic receptor agonist 
together with HAL (0.2mg/kg) or CLZ (10.0mg/kg) to postpartum-
rats.We examined which of these two agonists was able to reverse 
the disruptive effects induced by HAL or CLZ. We hypothesized 
that quinpirole, but not DOI, would be able to reverse the HAL-
induced disruption on maternal behavior and may also be effective 
in alleviating the CLZ-induced disruption to some extent. We had 
no prior conviction regarding the effect of DOI due to lack of suffi-
cient evidence in the literature on the role of serotonin in maternal 
behavior (Numan and Insel, 2003).
2. Materials and methods
2.1. Subjects
Animals were naive pregnant female Sprague–Dawley rats (9–12 
weeks old at the start of pregnancy) purchased from Charles River 
Inc. (Portage, MI). Upon arrival to our animal facility, the rats were 
between gestational days 13–15. Each subject was housed individu-
ally in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cage 
lined with aspen shavings in a colony on a 12-h light/dark cycle 
(lights on at 6:30 AM). All behavioral tests were performed in the 
light phase between 9:00 AM and 4:00 PM. The colony was main-
tained under standard vivarium conditions with an ambient tem-
perature of 23°C, relative humidity of 55–60%. Standard laboratory 
rat chow and water were available ad libitum. All animal procedures 
were approved by the University of Nebraska Institutional Animal 
Care and Use Committee.
2.2. Drugs and choices of doses
HAL (5.0 mg/ml ampoules, Sicor Pharmaceuticals, Inc, Irvine, 
CA) was diluted with sterile water. CLZ (a gift from NIMH drug 
supply program) was dissolved in 1.0% glacial acetic acid in dis-
tilled water. Quinpirole (QUI) and DOI (RBI-Sigma, Natick, MA) 
were dissolved in 0.9% saline. HAL (0.2 mg/kg), CLZ (10.0mg/kg), 
QUI (0.5 or 1.0 mg/kg), DOI (1.0 or 2.5 mg/kg) and vehicle (water 
or saline) were all administered subcutaneously in a volume of 1.0 
ml/kg body weight. Choices of drug doses for HAL and CLZ were 
based on our previous studies showing that, at these doses, HAL 
and CLZ effectively disrupt active maternal behaviors in rats (Li et 
al., 2004; Zhao and Li, 2009). The doses of QUI were chosen based 
on our preliminary study showing that 1.0mg/kg of QUI improved 
the HAL’s disruption on pup retrieval. DOI doses were chosen on 
the basis of reports showing that DOI at these doses potentiates 
the effects of amphetamine on dopamine release in the striatum, 
medial prefrontal cortex and nucleus accumbens (Ichikawa and-
Meltzer, 1995; Kuroki et al., 2003) and blocks the CLZ-induced 
dopamine release in the medial prefrontal cortex (Ichikawa et al., 
2001).
The RecepToR MechanisMs UndeRLying The disRUpTive effecTs of haLopeRidoL and cLoZapine on RaT MaTeRnaL BehavioR    435
3.1.2. QUI pretreatment dose-dependently improved the haloperidol-
induced maternal behavior deficits
As can be seen in Table 1 and Figure1A–C, both doses of QUI 
improved the HAL-induced deficits in pup approach, pup retrieval, 
pup licking and nest building, as described below.
3.1.2.1. Latency to approach and retrieve pups. QUI shortened the HAL-
induced increase in pup approach latency and the first and last pup 
retrieval latencies (Table 1). Both 0.5 and 1.0 mg/kg doses of QUI 
were effective in facilitating the HAL-treated dams to initiate contact 
with their pups and completely restored such behavior to the normal 
level (e.g., VEH+VEH group) across the testing period. For the pup 
retrieval latency, it appeared that both doses of QUI shortened the 
time the HAL-treated rats took to retrieve their first and last pups to 
the nest site and reinstated the first pup retrieval to the normal level 
at the 30, 120 and 240 min test points post-injection.
3.1.2.2. Number of pups retrieved. Both 0.5 and 1.0 mg/kg of QUI 
increased the number of pups retrieved in the HAL-treated rats 
and restored it to the normal level at certain time points of testing. 
Repeated measures ANOVA revealed that there was a significant 
interaction between the treatment groups and time points [F(20, 168) 
= 5.97, p < 0.001], a significant main effect of treatment groups [F(5, 
42) = 26.30, p < 0.001], and a significant effect of time points [F(4, 168) 
= 35.22, p < 0.001]. One-way ANOVA and post hoc tests showed 
that the QUI-0.5+HAL group was significantly different from the 
VEH+HAL group at the 30 and 120 min time points (Figure 1A, p < 
0.001 for 30 min, p = 0.022 for 120 min), whereas the QUI-1.0+HAL 
group differed from the VEH+HAL group at the 30, 120 and 240 min 
test points (Figure 1A, p < 0.001 for 30 and 120 min, p = 0.014 for 240 
min). Further analysis showed that the reversing effect of 0.5mg/
kg of QUI reached the control level at the 30 and 120 min test points 
while the 1.0 mg/kg of QUI restored the CLZ-induced disruption 
to the normal level at the 30, 120 and 240 min test pointswhen the 
two QUI+HAL groupswere compared with the VEH+VEH control 
group (Figure 1A, all ps > 0.10). It appears that the strongest reversal 
effect of QUI occurred 120 min after HAL administration (Figure 1A).
3.1.2.3. Pup licking. QUI produced a reversing effect on HAL-
induced pup licking deficit. Repeated measures ANOVA revealed a 
main effect of treatment groups [F(5, 42) = 4.56, p = 0.002], a significant 
effect of test time points [F(4, 168) = 7.71, p < 0.001], but no significant 
interaction between the two factors. One-way ANOVA and post hoc 
tests showed that both QUI groups differed significantly fromthe 
VEH+HAL group at the 120 min test point (Figure 1B, p = 0.045 for 
QUI-0.5+HAL group, p = 0.042 for QUI-1.0+HAL group). Further
CLZ (n = 8), QUI-1.0+CLZ (n = 8), DOI-1.0+CLZ (n = 8), and DOI-
2.5+CLZ (n = 8).
2.5. Data analysis
With the exception of latency data, various measurements of 
maternal behavior were expressed as mean ± SEM. To increase sta-
tistical power, we combined the two vehicle control groups from 
Experiments 1 and 2 into a single group since they did not differ sig-
nificantly on any measure (Independent-Samples T test or Mann–
Whitney U test, all ps > 0.10). Data were analyzed using a factorial 
repeated measures analysis of variance (ANOVA) with the between-
subjects factor being the treatment groups (e.g. saline, HAL) and the 
within-subjects factor being test time points (baseline, 30, 60, 120 
and 240 min post-injection). Group differences at different time 
points were further analyzed using simple main effect test (one-way 
ANOVA) followed by Turkey’s HSD post hoc tests where appro-
priate.
For the latency data, because they were not normally distributed 
(e.g. the cut-off time assigned 480 s for the latency data), these data 
were expressed as median ± interquartile range. Nonparametric 
Kruskal–Wallis test was used for analyzing the differences among 
the treatment groups. Once the overall significant effects were deter-
mined, two-group comparisons were performed using Mann–Whit-
ney U test. A conventional two-tailed level of significance at the 0.05 
level was required.
3. Results
3.1. Experiment 1. Effects of pretreatment with QUI or DOI on haloperi-
dol-induced maternal behavior deficits
3.1.1. Haloperidol treatment disrupted various components of maternal 
behavior
Consistent with our previous findings (Li et al., 2004; Zhao and 
Li, 2009), a single injection of HAL significantly disrupted various 
active components of maternal behavior (pup retrieval, pup lick-
ing, nest building, but not pup nursing). Rats treated with HAL took 
a much longer time to initiate contact with pups and retrieve their 
pups into the nest sites (Table 1) and retrieved fewer pups at the 30, 
60, 120 and 240 min test points (Figures 1, 2A) (0.001 < all ps < 0.05) 
compared to the vehicle-treated rats. They also spent less time lick-
ing their pups at the 30, 60 and 120 min test points and rebuilding 
the nest at the 30, 60, 120 and 240 min test points (Figures 1, 2B, C) 
(0.001 < all ps < 0.05). However, HAL treatment had no significant 
effect on nursing activity (Figures 1, 2D).
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6.18, p < 0.001], a significant main effect of treatment groups [F(5, 42) = 
17.52, p < 0.001], and a significant effect of testing time [F(4, 168) = 35.95, 
p < 0.001]. One-way ANOVA and post hoc tests showed that the 
QUI-0.5+HAL group was significantly different from the VEH+HAL 
group at the 120 and 240 min test points (both ps = 0.021), whereas 
the QUI-1.0+HAL group differed significantly from the VEH+HAL 
group at the 30, 120 and 240 min test points post-injection (Figure 
1C, all ps < 0.001). In particular, although both doses of QUI reversed 
analysis showed that the reversing effect reached the normal level 
when the two QUI+HAL groups were compared to the VEH+VEH 
control group (Figure1B, p = 0.85 for QUI-0.5+HAL group, p = 0.95 
for QUI-1.0+HAL group).
3.1.2.4. Nest building. Similar to the effect on pup retrieval and pup 
licking, both doses of QUI significantly improved the HAL-induced 
disruption of nest building activity. Repeatedmeasures ANOVA 
revealed a significant interaction between the two factors [F(20, 168) = 
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3.2.2. QUI pretreatment failed to improve the clozapine-induced maternal 
behavior deficits
In contrast to its effects on HAL-induced maternal behavior def-
icits, both doses of QUI had little effect on the CLZ-induced dis-
ruptions of pup approach, pup retrieval latency (Table 2), the num-
ber of pups retrieved and nest building (Figure 3A,C). Contrarily, 
QUI further potentiated the disruptive effect on these behaviors 
(Table 2, Figure 3A,C). Repeated measures ANOVA on the number 
of pups retrieved and nest building revealed a significant interac-
tion between the treatment groups and test time points [the num-
ber of pups retrieved: F(20, 168) = 9.56, p < 0.001; nest building: F(20, 168) 
= 2.77, p < 0.001], a significant main effect of treatment groups [the 
number of pups retrieved: F(5, 42) = 20.41, p < 0.001; nest building: 
F(5, 42) = 13.61, p < 0.001], and a significant effect of test time points 
[the number of pups retrieved: F(4, 168) = 61.43, p < 0.001; nest build-
ing: F(4, 168) = 38.33, p < 0.001]. One-way ANOVA and post hoc tests 
showed that the QUI-1.0+CLZ group differed significantly from the 
VEH+CLZ group in the number of pups retrieved and the duration 
of nest building at the 240 min test point (Figure 3A, C, p = 0.001 for 
the number of pups retrieved, p = 0.007 for the nest building), while 
the QUI-0.5+CLZ group differed from the VEH+CLZ group in nest 
building at the 240 min test point (Figure 3C, p = 0.026). QUI pretreat-
ment also did not improve the CLZ-induced deficits in pup licking 
and pup nursing activities (Figure 3B,D) at any test points. Repeated 
measures ANOVA on pup licking and pup nursing revealed a sig-
nificant interaction between the two factors [pup licking: F(20, 168) = 
1.68, p = 0.04; pup nursing: F(20, 168) = 2.05, p = 0.007], a significant main 
effect of treatment groups [pup licking: F(5, 42) = 4.47, p = 0.002; pup 
nursing: F(5, 42) = 5.52, p = 0.001], and a significant effect of test time 
points [pup licking: F(4, 168) = 8.02, p < 0.001; pup nursing: F(4, 168) = 6.72, 
p < 0.001]. Post hoc tests on pup licking and pup nursing revealed 
that there was no significant difference between the two QUI+CLZ 
groups and the VEH+CLZ group.
3.2.3. DOI pretreatment dose-dependently reversed the clozapine-induced 
maternal behavior deficits
As shown in Table 2 and Figure 4A,B, pretreatment of both doses 
of DOI (1.0 and 2.5 mg/kg) significantly improved the CLZ-induced 
disruption on pup approach, pup retrieval, and pup licking. How-
ever, the reversing effect of DOI on CLZ-induced disruption of nest 
building and pup nursing was not apparent (Figure 4C, D).
3.2.3.1. Latency to approach and retrieve pups. As shown in Table 2, both 
1.0 and 2.5 mg/kg of DOI shortened the prolonged approach latency 
induced by CLZ when the two DOI+CLZ groups were compared to 
the VEH+CLZ group and restored it to the normal level compared 
to the VEH+VEH group at the 30, 60 and 120 min test points (0.001 < 
all ps < 0.01). It also reduced the CLZ-induced deficits of the first pup 
the disruptive effect of HAL at the 120 min test point, only 1.0 mg/
kg of QUI was capable of improving it to the normal level when 
compared to the VEH+VEH group (Figure 1C, p = 0.34).
3.1.2.5. Pup nursing. As can be seen in Figure1D,QUI pretreatment 
had no significant effect on pup nursing. Repeatedmeasures ANOVA 
revealed a significant interaction between the two factors [F(20, 168) = 
2.14, p = 0.005], a significant main effect of treatment groups [F(5, 42) = 
4.66, p = 0.002], and a significant effect of testing time [F(4, 168) = 10.53, 
p < 0.001]. Post hoc tests showed that both QUI groups were not sig-
nificantly different from the VEH+HAL group (both ps > 0.10).
3.1.3. DOI pretreatment failed to improve the haloperidol-induced mater-
nal behavior deficits
Both 1.0 and 2.5 mg/kg of DOI failed to improve the HAL-induced 
disruption on pup approach and pup retrieval, as evidenced by no 
significant improvement in the approach latency nor in first and 
last pup retrieval latency (Table 1) when the two DOI+HAL groups 
were compared to the VEH+HAL group. Rather, 2.5 mg/kg of DOI 
further exacerbated the HAL-induced disruption on the approach 
latency at the 60 min test point (Table 1, p = 0.005). Post hoc tests 
on the number of pups retrieved, pup licking and nest building 
revealed that there was no significant difference between the two 
DOI+HAL groups and the VEH+HAL group. For pup nursing, one-
way ANOVA and post hoc tests indicated that the DOI-2.5+HAL 
group showed an even more suppressed nursing duration at the 30 
and 120 min test points compared to the VEH+HAL group (p = 0.048 
for 30 min, p = 0.041 for 120 min) (Figure 2D). The DOI-1.0+HAL 
group did not differ significantly from the VEH+HAL group across 
the testing period.
3.2. Experiment 2. Effects of pretreatment with QUI or DOI on clozapine-
induced maternal behavior deficits
3.2.1. Clozapine treatment impaired various components of maternal 
behavior
Consistent with our previous findings (Li et al., 2004; Zhao and Li, 
2009), the present study showed that a single injection of CLZ sig-
nificantly disrupted various active components of maternal behav-
ior and maintained such a disruptive effect for about 2 h. In com-
parison with the vehicle-treated ones, rats treated with CLZ took a 
much longer time to approach and retrieve their first pups into the 
nest sites (Table 2) at the 30, 60 and 120 min test points (0.001 < all 
ps < 0.01) and took longer to bring the last pups into the nest with 
less pups retrieved across the testing period (Table 2, Figures 3, 4A) 
(0.001 < all ps < 0.05). They also spent less time on pup licking, nest 
building and pup nursing at the 30, 60 and 120 min test points (Fig-
ures 3, 4B, C, D) (all ps < 0.05).
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3.2.3.2. Number of pups retrieved. Both doses of DOI increased the num-
ber of pups retrieved in the CLZ-treated rats. One-way ANOVA and 
post hoc tests showed that there was a significant difference between 
the DOI-1.0+CLZ group and the VEH+CLZ group at the 60 and 120 
min test points (p = 0.006 for 60 min, p = 0.008 for 120 min), whereas
retrieval and restored it to the normal level at the 60 min test point 
(p = 0.035) at a dose of 1.0 mg/kg as well as at the 60 and 120 min 
test points (both ps < 0.01) at a dose of 2.5 mg/kg. For the last pup 
retrieval latency, both doses of DOI completely rescued the disrup-
tion at the 60 and 120 min (0.001 < all ps < 0.01) test points. Further-
more, 2.5 mg/kg of DOI shortened the last pup retrieval latency at 
the 240 min test point (p = 0.001).
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and retrieval latency than those pretreated with vehicle. This result 
is in general agreement with a previous study showing that apo-
morphine, a mixed D1/D2 receptor agonist with a preferential affin-
ity and potency for the D2 over D1 receptor subtype (Kebabian and 
Calne, 1979), reversed HAL-induced pup retrieval deficits in post-
partum rats (Giordano et al., 1990). We extended this line of research 
by showing that HAL specifically acts on D2 receptors to achieve its 
disruptive effect. Of note, this finding does not necessarily rule out 
the involvement of the D1 receptor mechanism because HAL does 
have a weak D1 antagonism (Miyamoto et al., 2005), and other stud-
ies also find that D1 receptors are involved in the regulation of mater-
nal behavior (Miller and Lonstein, 2005; Numan et al., 2005; Numan 
and Stolzenberg, 2009).
The lack of the effect of DOI treatment on HAL-induced mater-
nal behavior deficits is not surprising given the fact that DOI is a 
selective 5-HT2A/2C agonist and HAL lacks an action on these sero-
tonergic receptor systems. Interestingly, DOI pretreatment further 
decreased the duration of pup nursing in the HAL-treated rats (see 
Figure 2D). Informal observations indicate that after the pups were 
returned to the cage, the HAL rats pretreated with 2.5 mg/kg of DOI 
did not approach and retrieve their pups, but stayed in the corner of 
the cage with no apparent movement. This may explain the reduc-
tion of pup nursing by DOI. In light that DOI itself reduces locomo-
tor activity (Hameleers et al., 2007; Krebs-Thomson and Geyer, 1996; 
Mittman and Geyer, 1991; Wing et al., 1990), it is possible that DOI-
induced hypolocomotor activity may have contributed to its disrup-
tive effect on pup nursing.
Our original hypothesis that QUI may also attenuate the CLZ-
induced disruption to some extent, as CLZ also possesses a D2 
antagonism, was not supported by the present findings. In contrast, 
QUI actually worsened some maternal behavior deficits, such as on 
pup retrieval and nest building. These findings indicate that CLZ-
induced maternal deficits are not primarily mediated by its weak 
antagonism of D2 receptor. Our preliminary work (data not shown) 
finds that QUI at a dose of 1.0 mg/kg by itself disrupts pup retrieval 
and nest building. Therefore, it is possible that a combination of clo-
zapine and QUI may provide an additive disruption on the CLZ-
induced maternal deficits.
The most striking finding from the present study was that DOI 
pretreatment rescued most, if not all, maternal behavior deficits 
induced by CLZ. We found that CLZ rats pretreated with DOI 
took a much shorter time to initiate contact with pups and retrieve 
their pups into the nest sites (Table 2), retrieved more pups (Fig-
ure 4A) and spent more time licking their pups than CLZ rats pre-
treated with vehicle (Figure 4B). CLZ has a unique and multifaceted 
pharmacological, behavioral and clinical profile in comparison with 
other antipsychotic drugs (Matsubara et al., 1993; Meltzer, 1989; Saf-
ferman et al., 1991; Schmauss et al., 1989) due to its multiple-receptor 
action, including a relatively high affinity for D4, histaminergic (H1), 
muscarinic, serotoninergic (5-HT2) and alpha-1-adrenergic recep-
tors (Baldessarini et al., 1992; Lane et al., 1988; Meltzer, 1989; Melt-
zer et al., 1989a; Miller and Hiley, 1974; Seeman, 1992; Zavitsanou 
et al., 2007), moderate affinity for D1, D2, D5, alpha-2-adrenergic and 
5-HT3 receptors (Ellenbroek et al., 1991; Matsubara et al., 1993; Miya-
moto et al., 2005; Murray and Waddington, 1990; Perry et al., 1983; 
Remington and Kapur, 2000). The unique antipsychotic property of 
CLZ (e.g., low EPS and less prolactin elevation) has been correlated 
with its lowaffinity and fast dissociation at the D2 receptor (Kapur 
and Remington, 2001; Kapur and Seeman, 2001; Seeman, 2002). This 
profile makes it difficult to pinpoint the exact mechanisms mediat-
ing the antipsychotic and behavioral effects of CLZ. Our finding that 
DOI dose-dependently improved the CLZ-induced maternal behav-
ior deficits suggests that CLZ exerts its disruptive effect on mater-
nal behavior through a 5-HT2A/2C receptor-mediated mechanism, 
and that this effect thus might not be directly related to its antipsy-
chotic efficacy, which is mediated by blockade of D2 receptors (See-
man, 2002).
the DOI-2.5+CLZ group differed significantly from the VEH+CLZ 
group even at the 240 min test point (Figure 4A, 0.001 < all ps < 0.05). 
Further analysis showed that the reversing effect of 1.0 mg/kg of 
DOI reached the normal level at the 60 and 120 min test points while 
the 2.5 mg/kg of DOI restored the CLZ-induced disruption to the 
normal level at 60, 120 and 240 min test points (Figure 4A, all ps > 
0.05). It appears that the strongest reversal effect of DOI occurred 120 
min after CLZ administration (Figure 4A).
3.2.3.3. Pup licking. Both doses of DOI alleviated the CLZ-induced 
disruption on pup licking. One-way ANOVA and post hoc tests 
showed that there was a significant difference between the DOI-
1.0+CLZ group and the VEH+CLZ group at the 120 min test point 
(p = 0.049), while the DOI-2.5+CLZ group differed significantly from 
the VEH+CLZ group at the 60 and 120 min test points (Figure 4B, p = 
0.034 for 60 min, p = 0.015 for 60 min). Further analysis showed that 
only 2.5 mg/kg of DOI restored this behavior to the normal level 
at the 60 and 120 min test points when the two DOI+CLZ groups 
were compared with the VEH+VEH control group (Figure 4B, both 
ps > 0.05).3.2.3.4. Nest building and pup nursing. Compared to the 
reversing effects on pup retrieval and pup licking, DOI at the cur-
rently tested doses appeared to be ineffective in reversing the CLZ-
induced deficits on nest building and pup nursing. Post hoc tests on 
nest building and pup nursing revealed that therewas no significant 
difference between the two DOI+CLZ groups and the VEH+CLZ 
group (Figure 4C, D, all ps > 0.05).
4. Discussion
The present study demonstrates an interesting double dissocia-
tion between dopamine and serotonin receptor mechanisms in the 
mediation of HAL- and CLZ-induced maternal behavior deficits in 
postpartum rats. Acute treatment of HAL and CLZ disrupted var-
ious components of rat maternal behavior. Pretreatment of QUI, a 
selective D2/D3 dopaminergic receptor agonist, but not DOI, a selec-
tive 5-HT2A/2C serotonergic receptor agonist, dose-dependently 
improved HAL-induced disruption of pup approach, pup retrieval, 
pup licking and nest building, whereas pretreatment of DOI, but not 
QUI, dose-dependently improved CLZ-induced disruptionof pup 
approach, pup retrieval and pup licking. These data strongly sug-
gest that the HAL-induced maternal deficits are primarily medi-
ated by its blockade of D2 dopamine receptors, whereas the CLZ-
induced maternal deficits are primarily mediated by the blockade of 
5-HT2A/2C receptors.
The dopamine systems have been well documented to play an 
important role in the regulation of maternal behavior. For exam-
ple, systemic (e.g., haloperidol, a D2 antagonist) or microinfusion 
of dopamine receptor antagonists such as SCH-23390 (a D1 antago-
nist), pimozide (a D2 antagonist) and cis-flupenthixol (a mixed D1/
D2 antagonist) into the specific brain regions implicated in maternal 
behavior (e.g., medial preoptic area, nucleus accumbens) disrupts 
various active maternal behaviors (Byrnes et al., 2002; Giordano et 
al., 1990; Keer and Stern, 1999; Li et al., 2004; Miller and Lonstein, 
2005; Numan et al., 2005; Numan and Stolzenberg, 2009; Silva et al., 
2001, 2003; Stern and Taylor, 1991). 6-OHDA lesion of the ventral 
striatum and ventral tegmental area disrupts pup retrieval (Hansen, 
1994; Hansen et al., 1991a,b). Additionally, mother–pup separation, 
which putatively enhances maternal motivation (Hansen, 1994), 
stimulates dopamine release in the ventral striatum of maternal rats 
(Hansen et al., 1993). Because HAL is primarily a D2 receptor antago-
nist, we hypothesized that it disrupts maternal behavior by blocking 
D2 dopamine receptors. We tested this hypothesis by co-administrat-
ing QUI, a selective D2/D3 agonist together with HAL and examined 
whether QUI could reverse the effects of HAL. As expected, QUI 
did significantly improve the HAL-induced maternal behavior defi-
cits. HAL rats pretreated with QUI showed shortened pup approach
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pup retrieval in postpartum rats (Miller and Lonstein, 2005; Numan 
et al., 2005). Microinfusion of a dopamine D1 receptor agonist SKF-
38393 into either the MPOA or the NA promotes the onset of mater-
nal behavior in pregnancy-terminated rats (Stolzenberg et al., 2007). 
However, it is unknown whether the D4 and/or D5 receptors are 
involved in the regulation of maternal behavior due to lack of evi-
dence. Alternatively, nest building activity may still be mediated by 
5-HT2A/2C receptors, but is more sensitive and vulnerable to pharma-
cological intervention (Li et al., 2004; Silva et al., 2001; Zhao and Li, 
2009). Future work should address this issue in detail.
The present study provides strong evidence supporting the 
involvement of 5-HT2A/2C receptors in the mediation of rat maternal 
behavior. Previous work on this issue is inadequate and inconsis-
tent. For example, Brunner et al. (1999) reported that 5-HT1B receptor 
knockout mother mice did not display pup retrieval deficits. More 
recently, Lerch-Haner et al. (2008) reported that transgenic mouse 
dams with a specific disruption in serotonin neuron development 
displayed profound maternal deficits (e.g., pup retrieval, pup nurs-
ing, nest building). This study, however, did not answer which sub-
types of 5-HT receptor are implicated in maternal activity. Other 
studies have found that 5-HT1B and 5-HT2A/2C receptors are involved 
in maternal aggressive behavior (De Almeida et al., 2005, 2006a,b; 
Olivier et al., 1995; Veiga et al., 2007). For example, intracerebroven-
tricular injections of DOI, a 5-HT2A/2C agonist, inhibited maternal 
aggression in postpartum female rats (De Almeida and Lucion, 
1994). To the best of our knowledge, the present study was the first 
to demonstrate that 5-HT2A/2C receptors may be important in regulat-
ing rat maternal behavior.
Consistent with our previous work (Li et al., 2004), we found that 
HAL and CLZ had different time courses of action. HAL tended to 
produce a prolonged disruption, whereas CLZ produced a tran-
sient one. For instance, the HAL-induced disruption of nest build-
ing was still apparent even at the 240 min test point (4 h post-injec-
tion), whereas the effect of CLZ was diminished (Figures 1, 3, C). It 
appears that the reversal effect of QUI on HAL-induced maternal 
deficits also differed in regard to time course of action from that of 
DOI on CLZ-induced deficits. For example, the reversal effect of DOI 
on CLZ-induced disruption of pup retrieval was somewhat delayed 
in onset when compared to that of quinpirole on HAL-induced 
impairment (Figures 1, 4A), which may be attributable to the rapid 
peak plasma concentration of quinpirole (Whitaker and Lindstrom, 
1987). Taken together, the present study demonstrates an interesting 
double dissociation receptor mechanism underlying the HAL and 
CLZ-induced maternal behavior deficits. Our data suggest that the 
HAL-induced maternal deficits are primarily mediated by the block-
ade of D2 dopamine receptors, whereas the CLZ-induced maternal 
deficits are primarily mediated by the blockade of 5-HT2A/2C recep-
tors. Because not all components of CLZ-induced maternal behav-
ior deficits were reversed by DOI, other receptor mechanisms such 
as the D1 receptor may also be involved, prompting the need for fur-
ther investigation.
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